Drug Combination Details
| General Information of the Combination (ID: C37670) | |||||
|---|---|---|---|---|---|
| Name | Ursodeoxycholic acid NP Info | + | Bezafibrate Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Autoimmune liver disease
[ICD-11: DB96]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vivo Model | Clinical trial | |||||
| Experimental
Result(s) |
Combination therapy of bezafibrate and UDCA improved biliary enzymes in non-cirrhotic Japanese patients with PBC refractory to UDCA. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatol Res. 2008 Jun;38(6):557-64. | |||
